samedan logo
 
 
spacer
home > pmps > winter 2008 > vaginal drug delivery: the progression of novel formulations
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Vaginal Drug Delivery: The Progression of Novel Formulations

Janet Halliday at CT Scotland considers why vaginal drug delivery has been relatively excluded from new design and technological development

In the world of drug delivery, oral controlled release, novel inhaled formulations and transdermal patches have all benefited from advances in design and technology. Of lesser volume of sales are products for vaginal administration, although there have been a number of new approaches which have been developed in recent years for vaginal delivery. This article reviews the range of these products, the areas of therapy, the regulatory environment and outlines advances on the horizon.

VAGINAL PRODUCTS

Products on the market for vaginal delivery include traditional formulations, such as creams and ointments, and also less familiar formulations, such as controlled-release vaginal inserts for cervical ripening (see Figure 1) and a sponge for contraception. Some examples of vaginal products are shown in Table 1. This list is not exhaustive, but gives a cross-section of the extensive range of products available.

AREAS OF THERAPY

As shown in Table 1, the areas of therapy are as diverse as the products themselves. Creams, ointments and pessaries for local treatment of infections and direct action on the cervix are familiar products for short-term or acute indications. More unusual presentations are exemplified by the controlled release vaginal insert for the indication of cervical ripening. Rings for contraception or HRT are also less familiar presentations of commonly used drugs (see Figure 2, page 36). These can be used over a period of three weeks to three months.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Janet Halliday is Director of Research and Development at Controlled Therapeutics in East Kilbride, Scotland, a wholly-owned subsidiary of Cytokine PharmaSciences Inc, King of Prussia, Pennsylvania in the US. Janet leads development projects both in partnership with other companies and on CT projects. As well as being responsible for directing work leading to new IP, she is involved in examining both in- and out-licensing opportunities. Janet joined CT as a Bench Formulation Scientist in 1988, initially working on solid dosage forms. She transferred to work on hydrogels and was involved in scale-up and process development for the first marketed product. Janet graduated in Pharmacy from Heriot Watt University, Edinburgh and studied for her PhD at the University of Strathclyde in Glasgow, in the formulation of metered dose inhaler suspensions in conjunction with Glaxo Wellcome
spacer
Dr Janet Halliday
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PHASTAR Names Chris Schoonmaker as Chief Operations Officer


More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

Aigenpulse

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement